Cognition Disorders Active Not Recruiting Phase 3 Trials for Solanezumab (DB11756)

IndicationStatusPhase
DBCOND0027877 (Cognition Disorders)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02008357Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory LossTreatment